Taylor & Francis Group
Browse
Supplemental Information.docx (37.65 kB)

Supplemental Information: OLIE, ITCC-082: A phase 2 trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma.docx

Download (37.65 kB)
dataset
posted on 2021-08-12, 10:17 authored by Nathalie Gaspar, Quentin Campbell-Hewson, Jie HuangJie Huang, Chinyere E. Okpara, Francisco Bautista

Supplemental Information - Definitions of study endpoints and relevant details

Funding

Eisai Inc.

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

History

Usage metrics

    Future Oncology

    Categories

    Keywords

    lenvatinibchemotherapyifosfamideetoposidetyrosine kinase inhibitorrelapsed-refractory osteosarcomapediatricadolescentyoung adultCancer Therapy (excl. Chemotherapy and Radiation Therapy)

    Licence

    CC BY-NC-ND 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC